Can Ebola be cured in course of time?

0
Mudassir Ali
Mar 10, 2020 06:42 PM 0 Answers
Member Since Dec 2019
Subscribed Subscribe Not subscribe
Flag(0)
Mudassir Ali
- Mar 10, 2020 06:42 PM

No ebolavirus-specific treatment exists. Treatment is primarily supportive in nature and includes minimizing invasive procedures, balancing fluids and electrolytes to counter dehydration, administration of platelets or fresh frozen plasma early in infection to prevent or controldisseminated intravascular coagulation, administration of procoagulants late in infection to control bleeding, maintaining oxygen levels, pain management, and the use of medications to treat bacterial or fungal secondary infections.Early treatment may increase the chance of survival.A number of experimental treatments are being studied.
In the United States, the FDA’s animal efficacy rule is being used to demonstrate reasonable safety to obtain permission to treat people who are infected with Ebola. It is being used as the normal path for testing drugs is not possible for diseases caused by dangerous pathogens or toxins. Experimental drugs are made available for use with the approval of regulatory agencies under named patient programs, known in the US as “expanded access”. The FDA has allowed two drugs, ZMapp and an RNA interference drug called TKM-Ebola, to be used in people infected with Ebola under these programs during the 2014 outbreak. As of Aug 14, 2014, the FDA has not approved any medications or vaccines to treat or prevent Ebola and advises people to watch out for fraudulent products.
The unavailability of experimental treatments in the most affected regions during the 2014 outbreak spurred controversy, with some calling for experimental drugs to be made more widely available in Africa on a humanitarian basis, and others warning that making unproven experimental drugs widely available would be unethical, especially in light of past experimentation conducted in developing countries by Western drug companies.
On 12 August the WHO released a statement that the use of not yet proven treatments is ethical in certain situations in an effort to treat or prevent the disease.
An experimental drug, ZMapp, consisting of three monoclonal antibodies produced in a plant, was first tested on humans in July 2014. It was administered to two Americans who had been infected with Ebola, and both appeared to have had positive results. ZMapp was also administered to a 75 year old Spanish priest with Ebola, who died and three Liberian health workers who showed improvement,although one of them later died. A British nurse was also being treated with ZMapp, and the manufacturer announced that its supplies had now been exhausted.
Favipiravir, an anti-viral drug approved in Japan for stockpiling against influenza pandemics, appears to be useful in a mouse model of Ebola. The Estrogen receptor drugs used to treat infertility and breast cancer (clomiphene and toremifene) inhibit the progress of Ebola virus in infected mice. Ninety percent of the mice treated with clomiphene and fifty percent of those treated with toremifene survived the tests. A 2014 study found that Amiodarone, an ion channel blockerused in the treatment of heart arrhythmias, blocks the entry of ebola virus into cells in vitro. Given their oral availability and history of human use, these drugs would be candidates for treating Ebola virus infection in remote geographical locations, either on their own or together with other antiviral drugs.
Other promising treatments rely on antisense technology. Both small interfering RNAs (siRNAs) and phosphorodiamidate morpholino oligomers (PMOs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein could prevent disease in nonhuman primates. TKM-Ebola is a small-interfering RNA compound, currently tested in a phase I clinical trial in people.Seven of eight Ebola patients survived after receiving treatment with a transfusion of blood donated by individuals who had previously survived the infection and were convalescing during an outbreak in the 1999 outbreak in the Democratic Republic of the Congo.
However, this potential treatment is considered controversial.
Intravenous antibodies appear to be protective in non-human primates who have been exposed to large doses of Ebola

Reply on This
Replying as Submit
0 Subscribers
Submit Answer
Please login to submit answer.
0 Answers